Journey: New Drug Application for DFD-29 for the Treatment of Rosacea OK

 Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that the FDA has accepted the Company’s New Drug Application (“NDA”) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024.

https://www.biospace.com/article/releases/journey-medical-corporation-announces-u-s-fda-acceptance-of-new-drug-application-for-dfd-29-for-the-treatment-of-rosaceaprescription-drug-user-fee-act-pdufa-goal-date-of-november-4-2024/